| Dec'19 | Dec'18 | Dec'17 | ||||
|---|---|---|---|---|---|---|
Operating expenses: | ||||||
Research and development | ||||||
36,359 | 22,649 | 7,684 | ||||
General and administrative | ||||||
8,013 | 4,165 | 1,456 | ||||
Total operating expenses | ||||||
44,372 | 26,814 | 9,140 | ||||
Loss from operations | ||||||
-44,372 | -26,814 | -9,140 | ||||
Interest income | ||||||
1,087 | 669 | 132 | ||||
Change in fair value of warrant liability | ||||||
- | 520 | 125 | ||||
Loss before income tax benefit | ||||||
-43,285 | -26,665 | -9,133 | ||||
Income tax benefit | ||||||
- | -187 | - | ||||
Accretion on Series A Convertible Redeemable Preferred Stock | ||||||
- | 276 | 343 | ||||
Net loss attributable to common stockholders | ||||||
-43,285 | -26,754 | -9,476 | ||||
Net loss per common share, basic and diluted | ||||||
-1.06 | -1.19 | -1.01 | ||||
Weighted average common shares outstanding, basic and diluted | ||||||
40,747 | 22,441 | 9,370 | ||||
Net Loss | ||||||
-43,285 | -26,478 | -9,133 | ||||